B cell maturation antigen | Tumour necrosis factor (TNF) receptor family | IUPHAR Guide to IMMUNOPHARMACOLOGY

Top ▲

B cell maturation antigen

  Target has curated data in GtoImmuPdb

Target id: 1889

Nomenclature: B cell maturation antigen

Abbreviated Name: BCMA

Systematic Nomenclature: TNFRSF17

Family: Tumour necrosis factor (TNF) receptor family

Annotation status:  image of a grey circle Awaiting annotation/under development. Please contact us if you can help with annotation.  » Email us

Gene and Protein Information
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 1 184 16p13.13 TNFRSF17 TNF receptor superfamily member 17
Mouse 1 185 Tnfrsf17 tumor necrosis factor receptor superfamily, member 17
Rat - - Tnfrsf17 TNF receptor superfamily member 17
Previous and Unofficial Names
tumor necrosis factor receptor superfamily, member 17 | BCM | CD269 | TNFRSF13a | tumor necrosis factor receptor superfamily
Database Links
ChEMBL Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
KEGG Gene
OMIM
UniProtKB
Wikipedia
Natural/Endogenous Ligands
APRIL {Sp: Human}
BAFF {Sp: Human}
Adaptor proteins (Human)
TRAF1, TRAF2, TRAF3, TRAF5, TRAF6
Other Binding Ligands
Key to terms and symbols Click column headers to sort
Ligand Sp. Action Affinity Parameter Reference
APRIL {Sp: Human} Hs - - -
BAFF {Sp: Human} Hs - - -
Immunopharmacology Comments
B-cell maturation antigen (BCMA) is a cell surface receptor for B-cell activating factor (BAFF). It interacts with various TRAF family adaptor proteins to modulate cell survival and proliferation, via NF-κB and MAPK8/JNK signal transduction pathways. BCMA is highly plasma cell-selective for malignant plasma cells from multiple myeloma (MM) patients, and is being investigated as a target for T-cell redirecting therapies to tackle relapsed/refractory MM [1,3]. Novel anti-BCMA therapeutic agents in early stage development for MM include monoclonal antibodies and CAR-T cells [2,4,6]. The antibody-drug conjugate GSK2857916 (IMGT identifier: 784) [5] is one of the early phase anti-BCMA clinical candidates being evaluated in patients with relapsed/refractory MM (see NCT02064387). GSK2857916 has received orphan drug designation from the EMA and FDA for MM.
Immuno Process Associations
Immuno Process:  Cytokine production & signalling
GO Annotations:  Associated to 1 GO processes
GO:0033209 tumor necrosis factor-mediated signaling pathway TAS
Immuno Process:  T cell (activation)
GO Annotations:  Associated to 1 GO processes, IEA only
click arrow to show/hide IEA associations
GO:0002250 adaptive immune response IEA
Immuno Process:  B cell (activation)
GO Annotations:  Associated to 1 GO processes, IEA only
click arrow to show/hide IEA associations
GO:0002250 adaptive immune response IEA
Immuno Process:  Immune regulation
GO Annotations:  Associated to 1 GO processes, IEA only
click arrow to show/hide IEA associations
GO:0002260 lymphocyte homeostasis IEA

References

Show »

1. Hengeveld PJ, Kersten MJ. (2015) B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy?. Blood Cancer J, 5: e282. [PMID:25723853]

2. Hipp S, Tai YT, Blanset D, Deegen P, Wahl J, Thomas O, Rattel B, Adam PJ, Anderson KC, Friedrich M. (2017) A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo. Leukemia, 31 (8): 1743-1751. [PMID:28025583]

3. Lee L, Bounds D, Paterson J, Herledan G, Sully K, Seestaller-Wehr LM, Fieles WE, Tunstead J, McCahon L, Germaschewski FM et al.. (2016) Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma. Br. J. Haematol., 174 (6): 911-22. [PMID:27313079]

4. Podar K, Pecherstorfer M. (2017) Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma. Expert Opin Pharmacother, 18 (11): 1061-1079. [PMID:28604120]

5. Tai YT, Mayes PA, Acharya C, Zhong MY, Cea M, Cagnetta A, Craigen J, Yates J, Gliddon L, Fieles W et al.. (2014) Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood, 123 (20): 3128-38. [PMID:24569262]

6. (2017) Sending CAR T Cells After Multiple Myeloma. Cancer Discov, 7 (8): OF9. [PMID:28588060]

Contributors

Show »

How to cite this page

David MacEwan.
Tumour necrosis factor (TNF) receptor family: B cell maturation antigen. Last modified on 08/11/2017. Accessed on 20/05/2019. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetoimmunopharmacology.org/GRAC/ObjectDisplayForward?objectId=1889.